The U.S. Food and Drug Administration (FDA) has issued a warning about counterfeit versions of the weight-loss drug Ozempic, also known as Wegovy, manufactured by Novo Nordisk. The FDA has seized thousands of units of the counterfeit drug, which are being sold through legitimate sources in the U.S.. The counterfeit Ozempic has been found to contain incorrect active ingredients, potentially causing harm to patients who are taking it for weight loss or diabetes management.
The counterfeit drugs were discovered after patients reported adverse events to the FDA. The agency is urging patients to check the serial and lot numbers on their prescriptions to ensure they have received the legitimate product.
Novo Nordisk is working closely with the FDA to investigate the supply chain and distribution channels of the counterfeit drugs. The counterfeit Ozempic has been found to have inconsistent packaging and labeling, as well as different colors and textures compared to the legitimate drug.
Counterfeit drugs are a significant concern and can pose serious risks to public health. The fake drug market is estimated to be worth $2.3 trillion and is driven by high demand and the potential for high profits. This seizure highlights the need for increased vigilance and regulation to combat counterfeit drugs and protect patient safety.
The FDA is advising healthcare professionals and patients to be cautious and report any suspected counterfeit drugs to the agency. They are also working with border forces and law enforcement agencies to prevent counterfeit drugs from entering the country.
Patients who have taken counterfeit Ozempic or experienced adverse events are encouraged to contact their healthcare providers and report the incident to the FDA.